Peter A Ward

List of Publications by Year in Descending Order

236 papers	22,995 citations	81 h-index	146 g-index
249 ext. papers	25,464 ext. citations	9.2 avg, IF	7.16 L-index

#	Paper	IF	Citations
236	Differential inflammatory responses of the native left and right ventricle associated with donor heart preservation. *Physiological Reports*, **2021**, 9, e15004	2.6	0
235	Role of Complement and Histones in Sepsis. *Frontiers in Medicine*, **2020**, 7, 616957	4.9	8
234	Requirement of Complement C6 for Intact Innate Immune Responses in Mice. *Journal of Immunology*, **2020**, 205, 251-260	5.3	8
233	Complement as a Major Inducer of Harmful Events in Infectious Sepsis. *Shock*, **2020**, 54, 595-605	3.4	13
232	Complement and Its Consequences in Sepsis **2019**, 504-507.e1		
231	Disruption of Neutrophil Extracellular Traps (NETs) Links Mechanical Strain to Post-traumatic Inflammation. *Frontiers in Immunology*, **2019**, 10, 2148	8.4	10
230	New strategies for treatment of infectious sepsis. *Journal of Leukocyte Biology*, **2019**, 106, 187-192	6.5	38
229	GM-CSF Administration Improves Defects in Innate Immunity and Sepsis Survival in Obese Diabetic Mice. *Journal of Immunology*, **2019**, 202, 931-942	5.3	11
228	Innate immune responses to trauma. *Nature Immunology*, **2018**, 19, 327-341	19.1	208
227	Role of complement C5a and histones in septic cardiomyopathy. *Molecular Immunology*, **2018**, 102, 32-41	4.3	25
226	Obesity and type 2 diabetes mellitus drive immune dysfunction, infection development, and sepsis mortality. *Journal of Leukocyte Biology*, **2018**, 104, 525-534	6.5	104
225	Harmful Roles of TLR3 and TLR9 in Cardiac Dysfunction Developing during Polymicrobial Sepsis. *BioMed Research International*, **2018**, 2018, 4302726	3	18
224	Selective Biological Responses of Phagocytes and Lungs to Purified Histones. *Journal of Innate Immunity*, **2017**, 9, 300-317	6.9	13
223	Complement and sepsis-induced heart dysfunction. *Molecular Immunology*, **2017**, 84, 57-64	4.3	30
222	Complement System **2017**, 785-812		
221	Understanding Immunosuppression after Sepsis. *Immunity*, **2017**, 47, 3-5	32.3	37
220	Diabetes and Sepsis: Risk, Recurrence, and Ruination. *Frontiers in Endocrinology*, **2017**, 8, 271	5.7	32

219	Complement-induced activation of MAPKs and Akt during sepsis: role in cardiac dysfunction. *FASEB Journal*, **2017**, 31, 4129-4139	0.9	32
218	Anti-inflammatory interventions-what has worked, not worked, and what may work in the future. *Translational Research*, **2016**, 167, 1-6	11	2
217	Therapeutic targeting of acute lung injury and acute respiratory distress syndrome. *Translational Research*, **2016**, 167, 183-91	11	107
216	Complement Destabilizes Cardiomyocyte Function In Vivo after Polymicrobial Sepsis and In Vitro. *Journal of Immunology*, **2016**, 197, 2353-61	5.3	35
215	Complement-induced activation of the cardiac NLRP3 inflammasome in sepsis. *FASEB Journal*, **2016**, 30, 3997-4006	0.9	67
214	The immune system's role in sepsis progression, resolution, and long-term outcome. *Immunological Reviews*, **2016**, 274, 330-353	11.3	286
213	Sepsis-induced immune dysfunction: can immune therapies reduce mortality?. *Journal of Clinical Investigation*, **2016**, 126, 23-31	15.9	309
212	Bidirectional Crosstalk between C5a Receptors and the NLRP3 Inflammasome in Macrophages and Monocytes. *Mediators of Inflammation*, **2016**, 2016, 1340156	4.3	28
211	New Insights into Molecular Mechanisms of Immune Complex-Induced Injury in Lung. *Frontiers in Immunology*, **2016**, 7, 86	8.4	18
210	Melatonin alleviates acute lung injury through inhibiting the NLRP3 inflammasome. *Journal of Pineal Research*, **2016**, 60, 405-14	10.4	146
209	Role of extracellular histones in the cardiomyopathy of sepsis. *FASEB Journal*, **2015**, 29, 2185-93	0.9	73
208	Organ distribution of histones after intravenous infusion of FITC histones or after sepsis. *Immunologic Research*, **2015**, 61, 177-86	4.3	30
207	The molecular fingerprint of lung inflammation after blunt chest trauma. *European Journal of Medical Research*, **2015**, 20, 70	4.8	29
206	Experimental Malaria in Pregnancy Induces Neurocognitive Injury in Uninfected Offspring via a C5a-C5a Receptor Dependent Pathway. *PLoS Pathogens*, **2015**, 11, e1005140	7.6	28
205	Experimental design of complement component 5a-induced acute lung injury (C5a-ALI): a role of CC-chemokine receptor type 5 during immune activation by anaphylatoxin. *FASEB Journal*, **2015**, 29, 3762-72	0.9	30
204	Resolvins on the way to resolution. *Journal of Experimental Medicine*, **2015**, 212, 1142	16.6	2
203	Cutting edge: critical role for C5aRs in the development of septic lymphopenia in mice. *Journal of Immunology*, **2015**, 194, 868-72	5.3	20
202	Inhibition of junctional adhesion molecule-A/LFA interaction attenuates leukocyte trafficking and inflammation in brain ischemia/reperfusion injury. *Neurobiology of Disease*, **2014**, 67, 57-70	7.5	56

201	Protein-based therapies for acute lung injury: targeting neutrophil extracellular traps. *Expert Opinion on Therapeutic Targets*, **2014**, 18, 703-14	6.4	37
200	Critical role for the NLRP3 inflammasome during acute lung injury. *Journal of Immunology*, **2014**, 192, 5974-83	5.3	202
199	Acute lung injury and the role of histones. *Translational Respiratory Medicine*, **2014**, 2, 1		30
198	Lung inflammation and damage induced by extracellular histones. *Inflammation and Cell Signaling*, **2014**, 1,		8
197	Interruption of macrophage-derived IL-27(p28) production by IL-10 during sepsis requires STAT3 but not SOCS3. *Journal of Immunology*, **2014**, 193, 5668-77	5.3	30
196	Tyrosine kinase 2 promotes sepsis-associated lethality by facilitating production of interleukin-27. *Journal of Leukocyte Biology*, **2014**, 96, 123-31	6.5	18
195	Persistent neutrophil dysfunction and suppression of acute lung injury in mice following cecal ligation and puncture sepsis. *Journal of Innate Immunity*, **2014**, 6, 695-705	6.9	23
194	Induction of M2 regulatory macrophages through the 2-adrenergic receptor with protection during endotoxemia and acute lung injury. *Journal of Innate Immunity*, **2014**, 6, 607-18	6.9	98
193	Modulation of inflammation by interleukin-27. *Journal of Leukocyte Biology*, **2013**, 94, 1159-65	6.5	64
192	The bipolar role of miR-466l in inflammation. *Immunity*, **2013**, 39, 801-2	32.3	1
191	Regulation of IL-17 family members by adrenal hormones during experimental sepsis in mice. *American Journal of Pathology*, **2013**, 182, 1124-30	5.8	22
190	The inflammatory response in sepsis. *Trends in Immunology*, **2013**, 34, 129-36	14.4	279
189	Extracellular histones are essential effectors of C5aR- and C5L2-mediated tissue damage and inflammation in acute lung injury. *FASEB Journal*, **2013**, 27, 5010-21	0.9	150
188	CD11c+ alveolar macrophages are a source of IL-23 during lipopolysaccharide-induced acute lung injury. *Shock*, **2013**, 39, 447-52	3.4	32
187	Changes and regulation of the C5a receptor on neutrophils during septic shock in humans. *Journal of Immunology*, **2013**, 190, 4215-25	5.3	71
186	The interaction between C5a and both C5aR and C5L2 receptors is required for production of G-CSF during acute inflammation. *European Journal of Immunology*, **2013**, 43, 1907-13	6.1	30
185	Zonulin as prehaptoglobin2 regulates lung permeability and activates the complement system. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2013**, 304, L863-72	5.8	38
184	An endogenous factor mediates shock-induced injury. *Nature Medicine*, **2013**, 19, 1368-9	50.5	12

183	Neuroendocrine Regulation Of The IL-27-Dependent Immune Response In Macrophages. *Blood*, **2013**, 122, 3460-3460	2.2	
182	Interactions between coagulation and complement--their role in inflammation. *Seminars in Immunopathology*, **2012**, 34, 151-65	12	280
181	Complement activation product C5a is a selective suppressor of TLR4-induced, but not TLR3-induced, production of IL-27(p28) from macrophages. *Journal of Immunology*, **2012**, 188, 5086-93	5.3	37
180	New approaches to the study of sepsis. *EMBO Molecular Medicine*, **2012**, 4, 1234-43	12	80
179	Fingerprinting of the TLR4-induced acute inflammatory response. *Experimental and Molecular Pathology*, **2012**, 93, 319-23	4.4	19
178	Evidence for anti-inflammatory effects of C5a on the innate IL-17A/IL-23 axis. *FASEB Journal*, **2012**, 26, 1640-51	0.9	55
177	A historical perspective on sepsis. *American Journal of Pathology*, **2012**, 181, 2-7	5.8	30
176	Therapeutic potential of targeting IL-17 and IL-23 in sepsis. *Clinical and Translational Medicine*, **2012**, 1, 4	5.7	29
175	New developments in C5a receptor signaling. *Cell Health and Cytoskeleton*, **2012**, 4, 73-82		37
174	Regulatory effects of C5a on IL-17A, IL-17F, and IL-23. *Frontiers in Immunology*, **2012**, 3, 387	8.4	24
173	Anti-inflammatory effects of 2 adrenergic receptor agonists in experimental acute lung injury. *FASEB Journal*, **2012**, 26, 2137-44	0.9	68
172	Manipulation of the complement system for benefit in sepsis. *Critical Care Research and Practice*, **2012**, 2012, 427607	1.5	22
171	Role of C3, C5 and anaphylatoxin receptors in acute lung injury and in sepsis. *Advances in Experimental Medicine and Biology*, **2012**, 946, 147-59	3.6	98
170	The outcome of polymicrobial sepsis is independent of T and B cells. *Shock*, **2011**, 36, 396-401	3.4	27
169	Oxidants and redox signaling in acute lung injury. *Comprehensive Physiology*, **2011**, 1, 1365-81	7.7	45
168	The complement system. *Cell and Tissue Research*, **2011**, 343, 227-35	4.2	498
167	Disturbances of the hypothalamic-pituitary-adrenal axis and plasma electrolytes during experimental sepsis. *Annals of Intensive Care*, **2011**, 1, 53	8.9	17
166	Role of endothelial chemokines and their receptors during inflammation. *Journal of Investigative Surgery*, **2011**, 24, 18-27	1.2	94

165	Complement dependency of cardiomyocyte release of mediators during sepsis. *FASEB Journal*, **2011**, 25, 2500-8	0.9	45
164	MyD88-dependent production of IL-17F is modulated by the anaphylatoxin C5a via the Akt signaling pathway. *FASEB Journal*, **2011**, 25, 4222-32	0.9	26
163	Do MDL-1+ cells play a broad role in acute inflammation?. *Journal of Clinical Investigation*, **2011**, 121, 4234-7	15.9	2
162	Oxidative stress: acute and progressive lung injury. *Annals of the New York Academy of Sciences*, **2010**, 1203, 53-9	6.5	101
161	Role of C5 activation products in sepsis. *Scientific World Journal, The*, **2010**, 10, 2395-402	2.2	24
160	The harmful role of c5a on innate immunity in sepsis. *Journal of Innate Immunity*, **2010**, 2, 439-45	6.9	112
159	Attenuation of IgG immune complex-induced acute lung injury by silencing C5aR in lung epithelial cells. *FASEB Journal*, **2009**, 23, 3808-18	0.9	39
158	Cross-talk between TLR4 and FcgammaReceptorIII (CD16) pathways. *PLoS Pathogens*, **2009**, 5, e1000464	7.6	67
157	Sepsis, complement and the dysregulated inflammatory response. *Journal of Cellular and Molecular Medicine*, **2009**, 13, 4154-60	5.6	53
156	Functions of C5a receptors. *Journal of Molecular Medicine*, **2009**, 87, 375-8	5.5	87
155	The sepsis seesaw: seeking a heart salve. *Nature Medicine*, **2009**, 15, 497-8	50.5	31
154	Immunodesign of experimental sepsis by cecal ligation and puncture. *Nature Protocols*, **2009**, 4, 31-6	18.8	1125
153	Inhibition of complement C5a prevents breakdown of the blood-brain barrier and pituitary dysfunction in experimental sepsis. *Critical Care*, **2009**, 13, R12	10.8	68
152	The first fifty years in research. *Annual Review of Pathology: Mechanisms of Disease*, **2009**, 4, 1-18	34	1
151	Upregulation of phagocyte-derived catecholamines augments the acute inflammatory response. *PLoS ONE*, **2009**, 4, e4414	3.7	114
150	The Role of Complement in Sepsis **2009**, 794-798		
149	Functional roles for C5a receptors in sepsis. *Nature Medicine*, **2008**, 14, 551-7	50.5	312
148	Harmful molecular mechanisms in sepsis. *Nature Reviews Immunology*, **2008**, 8, 776-87	36.5	862

147	On being a pathologist. *Human Pathology*, **2008**, 39, 1719-24	3.7	
146	Ability of antioxidant liposomes to prevent acute and progressive pulmonary injury. *Antioxidants and Redox Signaling*, **2008**, 10, 973-81	8.4	52
145	Acute lung injury induced by lipopolysaccharide is independent of complement activation. *Journal of Immunology*, **2008**, 180, 7664-72	5.3	98
144	C5 deficiency and C5a or C5aR blockade protects against cerebral malaria. *Journal of Experimental Medicine*, **2008**, 205, 1133-43	16.6	82
143	Functions of the complement components C3 and C5 during sepsis. *FASEB Journal*, **2008**, 22, 3483-90	0.9	54
142	Role of the complement in experimental sepsis. *Journal of Leukocyte Biology*, **2008**, 83, 467-70	6.5	36
141	Adverse functions of IL-17A in experimental sepsis. *FASEB Journal*, **2008**, 22, 2198-205	0.9	157
140	Molecular events in the cardiomyopathy of sepsis. *Molecular Medicine*, **2008**, 14, 327-36	6.2	90
139	The complement anaphylatoxin C5a induces apoptosis in adrenomedullary cells during experimental sepsis. *PLoS ONE*, **2008**, 3, e2560	3.7	39
138	Functional Roles for C5a Receptors in Sepsis. *FASEB Journal*, **2008**, 22, 48.10	0.9	
137	Inhibition of the alternative complement activation pathway in traumatic brain injury by a monoclonal anti-factor B antibody: a randomized placebo-controlled study in mice. *Journal of Neuroinflammation*, **2007**, 4, 13	10.1	86
136	STAT3 and suppressor of cytokine signaling 3: potential targets in lung inflammatory responses. *Expert Opinion on Therapeutic Targets*, **2007**, 11, 869-80	6.4	57
135	Phagocyte-derived catecholamines enhance acute inflammatory injury. *Nature*, **2007**, 449, 721-5	50.4	332
134	C5a-blockade improves burn-induced cardiac dysfunction. *Journal of Immunology*, **2007**, 178, 7902-10	5.3	39
133	Inflammatory Disorders **2007**, 1-5		
132	The phosphatidylinositol 3-kinase signaling pathway exerts protective effects during sepsis by controlling C5a-mediated activation of innate immune functions. *Journal of Immunology*, **2007**, 178, 5940-8	5.3	50
131	Complement-related molecular events in sepsis leading to heart failure. *Molecular Immunology*, **2007**, 44, 95-102	4.3	40
130	The disconnect between animal models of sepsis and human sepsis. *Journal of Leukocyte Biology*, **2007**, 81, 137-43	6.5	274

129	Role of oxidants in lung injury during sepsis. *Antioxidants and Redox Signaling*, **2007**, 9, 1991-2002	8.4	167
128	In vivo biological responses in the presence or absence of C3. *Advances in Experimental Medicine and Biology*, **2007**, 598, 240-50	3.6	1
127	Reduced neuronal cell death after experimental brain injury in mice lacking a functional alternative pathway of complement activation. *BMC Neuroscience*, **2006**, 7, 55	3.2	71
126	Attenuation of half sulfur mustard gas-induced acute lung injury in rats. *Journal of Applied Toxicology*, **2006**, 26, 126-31	4.1	82
125	Adenovirus-mediated in vivo silencing of anaphylatoxin receptor C5aR. *Journal of Biomedicine and Biotechnology*, **2006**, 2006, 28945		8
124	Adenoviral-mediated overexpression of SOCS3 enhances IgG immune complex-induced acute lung injury. *Journal of Immunology*, **2006**, 177, 612-20	5.3	28
123	Divergent signaling pathways in phagocytic cells during sepsis. *Journal of Immunology*, **2006**, 177, 1306-13	5.3	33
122	Regulation of lung inflammation in the model of IgG immune-complex injury. *Annual Review of Pathology: Mechanisms of Disease*, **2006**, 1, 215-42	34	43
121	An essential role for complement C5a in the pathogenesis of septic cardiac dysfunction. *Journal of Experimental Medicine*, **2006**, 203, 53-61	16.6	108
120	Better understanding of organ dysfunction requires proteomic involvement. *Journal of Proteome Research*, **2006**, 5, 1060-2	5.6	10
119	Complement in lung disease. *Autoimmunity*, **2006**, 39, 387-94	3	46
118	In vivo regulation of neutrophil apoptosis by C5a during sepsis. *Journal of Leukocyte Biology*, **2006**, 80, 1575-83	6.5	57
117	C5a, a therapeutic target in sepsis. *Recent Patents on Anti-infective Drug Discovery*, **2006**, 1, 57-65	1.6	24
116	Generation of C5a in the absence of C3: a new complement activation pathway. *Nature Medicine*, **2006**, 12, 682-7	50.5	746
115	New insights into cellular mechanisms during sepsis. *Immunologic Research*, **2006**, 34, 133-41	4.3	25
114	Relationship of acute lung inflammatory injury to Fas/FasL system. *American Journal of Pathology*, **2005**, 166, 685-94	5.8	65
113	Chapter 12 Endothelial cell injury and defense. *Advances in Molecular and Cell Biology*, **2005**, 335-364		0
112	Role of C5a in inflammatory responses. *Annual Review of Immunology*, **2005**, 23, 821-52	34.7	715

111	Harmful and protective roles of neutrophils in sepsis. *Shock*, **2005**, 24, 40-7	3.4	105
110	Evaluation of endotoxin models for the study of sepsis. *Shock*, **2005**, 24 Suppl 1, 7-11	3.4	134
109	Complement-induced Impairment of the Innate Immune System During Sepsis. *Current Infectious Disease Reports*, **2005**, 7, 349-54	3.9	7
108	Evidence for a functional role of the second C5a receptor C5L2. *FASEB Journal*, **2005**, 19, 1003-5	0.9	114
107	Changes in the novel orphan, C5a receptor (C5L2), during experimental sepsis and sepsis in humans. *Journal of Immunology*, **2005**, 174, 1104-10	5.3	69
106	Regulatory role of C5a in LPS-induced IL-6 production by neutrophils during sepsis. *FASEB Journal*, **2004**, 18, 370-2	0.9	122
105	Regulatory role of C5a on macrophage migration inhibitory factor release from neutrophils. *Journal of Immunology*, **2004**, 173, 1355-9	5.3	55
104	Role of C5a-C5aR interaction in sepsis. *Shock*, **2004**, 21, 1-7	3.4	78
103	Stat3 activation in acute lung injury. *Journal of Immunology*, **2004**, 172, 7703-12	5.3	86
102	The dark side of C5a in sepsis. *Nature Reviews Immunology*, **2004**, 4, 133-42	36.5	337
101	Complement-induced impairment of the innate immune system during sepsis. *Current Allergy and Asthma Reports*, **2004**, 4, 359-64	5.6	6
100	Selectin inhibition modulates Akt/MAPK signaling and chemokine expression after liver ischemia-reperfusion. *Journal of Investigative Surgery*, **2004**, 17, 303-13	1.2	35
99	Mechanisms of inflammatory response syndrome in sepsis. *Drug Discovery Today Disease Mechanisms*, **2004**, 1, 345-350		9
98	C5a-induced gene expression in human umbilical vein endothelial cells. *American Journal of Pathology*, **2004**, 164, 849-59	5.8	134
97	Disturbed homeostasis of lung intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 during sepsis. *American Journal of Pathology*, **2004**, 164, 1435-45	5.8	45
96	Novel chemokine responsiveness and mobilization of neutrophils during sepsis. *American Journal of Pathology*, **2004**, 165, 2187-96	5.8	122
95	Role of Complement in Multi-Organ Dysfunction Syndrome **2004**, 465-480		
94	Structure-function relationships of human C5a and C5aR. *Journal of Immunology*, **2003**, 170, 6115-24	5.3	48

93	Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression. *Journal of Immunology*, **2003**, 170, 503-7	5.3	264
92	Anti-inflammatory strategies for the treatment of sepsis. *Expert Opinion on Biological Therapy*, **2003**, 3, 339-50	5.4	27
91	Murine complement interactions with Pseudomonas aeruginosa and their consequences during pneumonia. *American Journal of Respiratory Cell and Molecular Biology*, **2003**, 29, 432-8	5.7	34
90	Novel strategies for the treatment of sepsis. *Nature Medicine*, **2003**, 9, 517-24	50.5	682
89	Regulation by C5a of neutrophil activation during sepsis. *Immunity*, **2003**, 19, 193-202	32.3	93
88	Neutrophil C5a receptor and the outcome in a rat model of sepsis. *FASEB Journal*, **2003**, 17, 1889-91	0.9	69
87	A key role of C5a/C5aR activation for the development of sepsis. *Journal of Leukocyte Biology*, **2003**, 74, 966-70	6.5	34
86	Anti-complement strategies in experimental sepsis. *Scandinavian Journal of Infectious Diseases*, **2003**, 35, 601-3		12
85	The enigma of sepsis. *Journal of Clinical Investigation*, **2003**, 112, 460-7	15.9	216
84	The enigma of sepsis. *Journal of Clinical Investigation*, **2003**, 112, 460-467	15.9	433
83	Mediators and regulation of neutrophil accumulation in inflammatory responses in lung: insights from the IgG immune complex model. *Free Radical Biology and Medicine*, **2002**, 33, 303-10	7.8	124
82	Protection from half-mustard-gas-induced acute lung injury in the rat. *Journal of Applied Toxicology*, **2002**, 22, 257-62	4.1	68
81	Endogenous regulation of the acute inflammatory response. *Molecular and Cellular Biochemistry*, **2002**, 234/235, 225-228	4.2	42
80	Complement-induced impairment of innate immunity during sepsis. *Journal of Immunology*, **2002**, 169, 3223-31	5.3	154
79	Protection of innate immunity by C5aR antagonist in septic mice. *FASEB Journal*, **2002**, 16, 1567-74	0.9	141
78	Altered neutrophil trafficking during sepsis. *Journal of Immunology*, **2002**, 169, 307-14	5.3	62
77	Expression and function of C5a receptor in mouse microvascular endothelial cells. *Journal of Immunology*, **2002**, 169, 5962-70	5.3	135
76	C5a receptor and thymocyte apoptosis in sepsis. *FASEB Journal*, **2002**, 16, 887-8	0.9	75

75	Expression and function of the C5a receptor in rat alveolar epithelial cells. *Journal of Immunology*, **2002**, 168, 1919-25	5.3	80
74	Role of nitric oxide in acute lung inflammation: lessons learned from the inducible nitric oxide synthase knockout mouse. *Critical Care Medicine*, **2002**, 30, 1960-8	1.4	40
73	Anti-c5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis. *American Journal of Pathology*, **2002**, 160, 1867-75	5.8	141
72	Activator protein-1 activation in acute lung injury. *American Journal of Pathology*, **2002**, 161, 275-82	5.8	38
71	Generation of C5a by phagocytic cells. *American Journal of Pathology*, **2002**, 161, 1849-59	5.8	174
70	Increased C5a receptor expression in sepsis. *Journal of Clinical Investigation*, **2002**, 110, 101-108	15.9	130
69	Increased C5a receptor expression in sepsis. *Journal of Clinical Investigation*, **2002**, 110, 101-8	15.9	71
68	Endogenous regulation of the acute inflammatory response. *Molecular and Cellular Biochemistry*, **2002**, 234-235, 225-8	4.2	17
67	Regulation of experimental lung inflammation. *Respiration Physiology*, **2001**, 128, 17-22		66
66	Protective effects of anti-C5a peptide antibodies in experimental sepsis. *FASEB Journal*, **2001**, 15, 568-70	0.9	114
65	Role of C5a in multiorgan failure during sepsis. *Journal of Immunology*, **2001**, 166, 1193-9	5.3	190
64	Regulatory effects of eotaxin on acute lung inflammatory injury. *Journal of Immunology*, **2001**, 166, 5208-18	5.3	19
63	Role of IL-18 in acute lung inflammation. *Journal of Immunology*, **2001**, 167, 7060-8	5.3	87
62	Molecular signatures of sepsis: multiorgan gene expression profiles of systemic inflammation. *American Journal of Pathology*, **2001**, 159, 1199-209	5.8	173
61	Exogenous and endogenous nitric oxide but not iNOS inhibition improves function and survival of ischemically injured livers. *Journal of Investigative Surgery*, **2001**, 14, 267-73	1.2	27
60	Neutrophil depletion and chemokine response after liver ischemia and reperfusion. *Journal of Investigative Surgery*, **2001**, 14, 99-107	1.2	33
59	Systemic and lung physiological changes in rats after intravascular activation of complement. *Journal of Applied Physiology*, **2001**, 90, 2289-95	3.7	23
58	Leukocyte recruitment and the acute inflammatory response. *Brain Pathology*, **2000**, 10, 127-35	6	81

57	Protective effects of anti-C5a in sepsis-induced thymocyte apoptosis. *Journal of Clinical Investigation*, **2000**, 106, 1271-80	15.9	120
56	Regulation of inflammatory vascular damage. *Journal of Pathology*, **2000**, 190, 343-8	9.4	119
55	Role of CC chemokines (macrophage inflammatory protein-1 beta, monocyte chemoattractant protein-1, RANTES) in acute lung injury in rats. *Journal of Immunology*, **2000**, 164, 2650-9	5.3	119
54	Adhesion molecules in liver ischemia and reperfusion. *Journal of Surgical Research*, **2000**, 94, 185-94	2.5	60
53	Anti-inflammatory effects of mutant forms of secretory leukocyte protease inhibitor. *American Journal of Pathology*, **2000**, 156, 1033-9	5.8	47
52	Regulation of inflammatory vascular damage **2000**, 190, 343		3
51	Role of chemotactic factors in neutrophil activation after thermal injury in rats. *Cellular and Molecular Neurobiology*, **1999**, 23, 371-85	4.6	25
50	Roles for C-X-C chemokines and C5a in lung injury after hindlimb ischemia-reperfusion. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **1999**, 276, L57-63	5.8	27
49	Endothelial cell determinants of susceptibility to neutrophil-mediated killing. *Shock*, **1999**, 12, 111-7	3.4	26
48	Essential role of alveolar macrophages in intrapulmonary activation of NF-kappaB. *American Journal of Respiratory Cell and Molecular Biology*, **1999**, 20, 692-8	5.7	117
47	Protective effects of C5a blockade in sepsis. *Nature Medicine*, **1999**, 5, 788-92	50.5	349
46	Requirement for interleukin-12 in the pathogenesis of warm hepatic ischemia/reperfusion injury in mice. *Hepatology*, **1999**, 30, 1448-53	11.2	99
45	Inhibition of NF-kappaB activation and augmentation of IkappaBbeta by secretory leukocyte protease inhibitor during lung inflammation. *American Journal of Pathology*, **1999**, 154, 239-47	5.8	143
44	Synergistic enhancement of chemokine generation and lung injury by C5a or the membrane attack complex of complement. *American Journal of Pathology*, **1999**, 154, 1513-24	5.8	44
43	Molecular cloning and characterization of a novel human CC chemokine, SCYA26. *Genomics*, **1999**, 58, 313-7	4.3	12
42	Regulatory effects of interleukin-11 during acute lung inflammatory injury. *Journal of Leukocyte Biology*, **1999**, 66, 151-157	6.5	13
41	Neutrophil adhesion to human endothelial cells is induced by the membrane attack complex: the roles of P-selectin and platelet activating factor. *Inflammation*, **1998**, 22, 583-98	5.1	43
40	Cytokine and adhesion molecule requirements for lung injury induced by anti-glomerular basement membrane antibody. *Inflammation*, **1998**, 22, 403-17	5.1	5

39	Heterogeneity of vascular endothelial cells: differences in susceptibility to neutrophil-mediated injury. *Microvascular Research*, **1998**, 56, 203-11	3.7	54
38	Differing patterns of P-selectin expression in lung injury. *American Journal of Pathology*, **1998**, 153, 1113-22	5.2	30
37	Role of complement in in vitro and in vivo lung inflammatory reactions. *Journal of Leukocyte Biology* , **1998**, 64, 40-8	6.5	49
36	Blood mononuclear cell production of TNF-alpha and IL-8: engagement of different signal transduction pathways including the p42 MAP kinase pathway. *Journal of Leukocyte Biology*, **1998**, 64, 124-33	6.5	13
35	A sulfatide receptor distinct from L-selectin is involved in lymphocyte activation. *FEBS Letters*, **1997** , 418, 310-4	3.8	14
34	Recruitment of inflammatory cells into lung: roles of cytokines, adhesion molecules, and complement. *Translational Research*, **1997**, 129, 400-4		36
33	Cytokine responses of human blood monocytes stimulated with Igs. *Inflammation*, **1997**, 21, 501-17	5.1	22
32	Role of complement, chemokines, and regulatory cytokines in acute lung injury. *Annals of the New York Academy of Sciences*, **1996**, 796, 104-12	6.5	118
31	Inflammatory mediators, cytokines, and adhesion molecules in pulmonary inflammation and injury. *Advances in Immunology*, **1996**, 62, 257-304	5.6	80
30	The role of cytokines and adhesion molecules in the development of inflammatory injury. *Trends in Molecular Medicine*, **1995**, 1, 40-5		122
29	Adhesion molecules and inflammatory injury. *FASEB Journal*, **1994**, 8, 504-512	0.9	841
28	Mechanisms of neutrophil-mediated injury. *Clinical and Experimental Immunology*, **1993**, 93 Suppl 1, 2	6.2	1
27	Protective effects of oligosaccharides in P-selectin-dependent lung injury. *Nature*, **1993**, 364, 149-51	50.4	297
26	Mechanism of neutrophil-induced xanthine dehydrogenase to xanthine oxidase conversion in endothelial cells: evidence of a role for elastase. *American Journal of Respiratory Cell and Molecular Biology*, **1992**, 6, 270-8	5.7	67
25	Hydrogen peroxide-induced cell and tissue injury: protective effects of Mn2+. *Inflammation*, **1991**, 15, 291-301	5.1	33
24	Effects of adenosine on inositol 1,4,5-trisphosphate formation and intracellular calcium changes in formyl-Met-Leu-Phe-stimulated human neutrophils. *Journal of Leukocyte Biology*, **1990**, 48, 281-3	6.5	23
23	Iloprost inhibits neutrophil-induced lung injury and neutrophil adherence to endothelial monolayers. *American Journal of Respiratory Cell and Molecular Biology*, **1990**, 3, 301-9	5.7	71
22	Mediator-induced activation of xanthine oxidase in endothelial cells. *FASEB Journal*, **1989**, 3, 2512-8	0.9	190

21	Rapid induction of neutrophil-endothelial adhesion by endothelial complement fixation. *Nature*, **1989**, 339, 314-7	50.4	140
20	Measurement of intracellular fluorescence of human monocytes relative to oxidative metabolism. *Journal of Leukocyte Biology*, **1988**, 43, 304-10	6.5	111
19	Formyl peptide chemotaxis receptors on the rat neutrophil: experimental evidence for negative cooperativity. *Journal of Cellular Biochemistry*, **1985**, 27, 359-75	4.7	13
18	A comparative study of pulmonary fibrosis induced by bleomycin and an O2 metabolite producing enzyme system. *Chest*, **1983**, 83, 44S-45S	5.3	17
17	Suppression of acute and chronic inflammation by orally administered prostaglandins. *Arthritis and Rheumatism*, **1981**, 24, 1151-8		48
16	Acute immunologic pulmonary alveolitis. *Journal of Clinical Investigation*, **1974**, 54, 349-57	15.9	196
15	The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. *Journal of Experimental Medicine*, **1971**, 133, 885-900	16.6	341
14	Complement-derived leukotactic factors in inflammatory synovial fluids of humans. *Journal of Clinical Investigation*, **1971**, 50, 606-16	15.9	154
13	The production by antigen-stimulated lymphocytes of a leukotactic factor distinct from migration inhibitory factor. *Cellular Immunology*, **1970**, 1, 162-74	4.4	188
12	The requirement of serine esterase function in complement-dependent erythrophagocytosis. *Journal of Experimental Medicine*, **1969**, 130, 745-64	16.6	49
11	Esterases of the polymorphonuclear leukocyte capable of hydrolyzing acetyl DL-phenyl-alanine beta-naphthyl ester. Relationship to the activatable esterase of chemotaxis. *Journal of Experimental Medicine*, **1969**, 129, 569-84	16.6	32
10	The deactivation of rabbit neutrophils by chemotactic factor and the nature of the activatable esterase. *Journal of Experimental Medicine*, **1968**, 127, 693-709	16.6	225
9	Mechanisms of the inhibition of chemotaxis by phosphonate esters. *Journal of Experimental Medicine*, **1967**, 125, 1001-20	16.6	86
8	Partial biochemical characterization of the activated esterase required in the complement-dependent chemotaxis of rabbit polymorphonuclear leukocytes. *Journal of Experimental Medicine*, **1967**, 125, 1021-30	16.6	51
7	Generation of chemotactic activity in rabbit serum by plasminogen-streptokinase mixtures. *Journal of Experimental Medicine*, **1967**, 126, 149-58	16.6	50
6	The chemosuppression of chemotaxis. *Journal of Experimental Medicine*, **1966**, 124, 209-26	16.6	215
5	BOUND COMPLEMENT AND IMMUNOLOGIC INJURY OF BLOOD VESSELS. *Journal of Experimental Medicine*, **1965**, 121, 215-34	16.6	222
4	THE ROLE OF SERUM COMPLEMENT IN CHEMOTAXIS OF LEUKOCYTES IN VITRO. *Journal of Experimental Medicine*, **1965**, 122, 327-46	16.6	366

3	Studies on the adjuvant action of bacterial endotoxins on antibody formation. III. Histologic response of the rabbit spleen to a single injection of a purified protein antigen. *Journal of Experimental Medicine*, **1959**, 109, 463-74	16.6	62
2	Acute and Chronic Inflammation1-16		10
1	The Role of the Endothelium in Systemic Inflammatory Response Syndrome and Sepsis1294-1302		